Prialt Overview

  • Status
  • Acquired/​Merged
  • Employees
  • 34
Employees
  • Latest Deal Type
  • Buyout/​LBO
  • Financing Rounds
  • 2

Prialt General Information

Description

Developer of medicines designed to reduce severe chronic pain in adult patients. The company's medicines work on pain transmission by binding to the N-type calcium channels in the spinal cord that send pain signals enabling patients to reduce chronic pain.

Contact Information

Website
www.prialt.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Prialt Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Prialt‘s full profile, request access.

Request a free trial

Prialt Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prialt Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Prialt‘s full profile, request access.

Request a free trial